摘要
目的 研究酪氨酸激酶抑制剂STI5 71与三氧化二砷 (As2 O3 )联合应用对多药耐药bcr abl阳性白血病细胞的协同效应。方法 采用MTT法比较STI5 71单独或与不同浓度的As2 O3 联合应用对bcr abl和mdr1共同阳性的白血病细胞系K5 6 2 n/VCR的抑制作用。结果 1μmol/L的STI5 71对K5 6 2 n/VCR细胞无明显细胞毒作用 ,与 10 -5,10 -6,10 -7,10 -8mol/L的As2 O3 联合应用 ,细胞毒作用明显增强。As2 O3 单独对K5 6 2 n/VCR细胞的IC50 为 1.879μmol/L ,加STI5 71后 ,IC50 为 0 .15 5 μmol/L ,协同抑制作用为 12 .12倍。结论 STI5 71与As2 O3 联合应用对于bcr
Objective To study the synergistic effect of STI571, an inhibitor of tyrosine kinase in combination with arsenic trioxide (As_2O_3) on a multidrug-resistant leukemia cell line expressing bcr-abl. MethodsThe cytotoxic effect of STI571 alone or in combination with different concentrations of As_2O_3 on both bcr-abl and mdr1 positive leukemia cell line K562-n/VCR was detected by MTT method. Results The cytotoxic effect of STI571 (1 μmol/L) combined with As_2O_3 at concentrations 10^(-5), 10^(-6), 10^(-7), 10^(-8) mol/L (IC_(50) 0.155 μmol/L) on K562-n/VCR cells was significantly higher than that of As_2O_3 alone (IC_(50) 1.879 μmol/L). The synergistic interaction on K562-n/VCR cells increased the cytotoxic effect by 12.1-fold. Conclusion Combination of STI571 with As_2O_3 has a synergistic inhibiting effect on leukemia cells expressing bcr-abl and mdr1.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2004年第9期535-537,共3页
Chinese Journal of Oncology
基金
国家自然科学基金资助项目 ( 3 9770 3 3 0 )
